# Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease

> **NCT06765993** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Lunan Better Pharmaceutical Co., LTD.** · enrollment: 234 (estimated)

## Conditions studied

- Meniere´s Disease

## Interventions

- **DRUG:** Isosorbide oral solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06765993
- **Lead sponsor:** Lunan Better Pharmaceutical Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 234 (ESTIMATED)
- **Last updated:** 2025-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06765993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06765993, "Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT06765993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*